These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 9784798)

  • 1. Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease.
    Harbison JW
    Am J Health Syst Pharm; 1998 Oct; 55(19 Suppl 1):S17-20. PubMed ID: 9784798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
    Tran H; Anand SS
    JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG; Parekh A; Ezekowitz MD
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet therapy in the prevention of stroke.
    Easton JD
    Drugs; 1991; 42 Suppl 5():39-50. PubMed ID: 1726215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel for cerebrovascular prevention.
    Paciaroni M; Bogousslavsky J
    Cerebrovasc Dis; 1999; 9(5):253-60. PubMed ID: 10473907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet Therapy After Noncardioembolic Stroke.
    Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
    Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy.
    Habib GB
    Clin Cardiol; 2006 Jun; 29(6):244-8. PubMed ID: 16796073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases.
    Bhatt DL; Kapadia SR; Yadav JS; Topol EJ
    Cerebrovasc Dis; 2000; 10 Suppl 5():34-40. PubMed ID: 11096181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
    Valentine N; Van de Laar FA; van Driel ML
    Cochrane Database Syst Rev; 2012 Nov; 11():CD005449. PubMed ID: 23152231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What have we learned from recent antiplatelet trials?
    Easton JD
    Neurology; 1998 Sep; 51(3 Suppl 3):S36-8. PubMed ID: 9744831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapy in cerebrovascular disorders.
    Weber R; Brenck J; Diener HC
    Handb Exp Pharmacol; 2012; (210):519-46. PubMed ID: 22918745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Stroke; 2000 Jul; 31(7):1779-84. PubMed ID: 10884487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
    Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
    PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
    Lenz T; Wilson A
    Clin Pharmacokinet; 2003; 42(10):909-20. PubMed ID: 12885264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.